Acute myeloid leukemia (AML) is predominantly a disease of older age, with a median age
of 68 years at diagnosis. 1 Older and unfit adults with AML (herein defined as age $60 …

Acute myeloid leukemia (AML) is a disease of older adults, with a median age of 67 years at
presentation. In the past, only a third of older patients (defined as individuals older than 60 …

Introduction Acute myeloid leukemia (AML), a disease affecting primarily older adults with a
median age at presentation of approximately 68 years, continues to pose significant …

Advances in molecular diagnostics and drug development have ushered an era of precision
oncology in acute myeloid leukemia (AML). The availability of effective molecularly targeted …

Opinion statement Older patients with acute myelogenous leukemia (AML) fare much less
well than younger patients with the same disease due to a combination of comorbidities and …

Abstract Purpose of Review Acute myeloid leukemia (AML) is a disease of the elderly, with a
median age of diagnosis in the sixth decade of life. Mortality has declined over the last few …

Most patients with newly diagnosed acute myeloid leukemia (AML) are 65 years or older.
The treatment of AML in older patients has been characterized by distinct patient-and …

Introduction Acute myeloid leukemia (AML) is an aggressive disease predominantly
affecting the elderly population. The elderly population represents a challenging group to …

Although anthracycline and cytarabine-based therapy remains the standard of care for older
patients with AML, this option remains suboptimal for the vast majority of patients. We argue …

Acute myeloid leukemia (AML) is more prevalent in older adults, with an incidence in the
United States of 17.6 per 100,000 for those⩾ 65 years of age, compared with an incidence of …